Author, year | Sample size R/A* | Age (years) | Women (%) | Diagnostic criteria | Cancer | Intervention T/C* | Anticancer therapies | Practice mode | Outcomes |
---|---|---|---|---|---|---|---|---|---|
Chen et al. [26] | 120/120 | T: 64.1 ± 6.3 C: 60.0 ± 9.1 | 70.0 | Depression: CCMD-3 | Lung and breast cancers; any stage | T: Xuefuzhuyu decoction,1 dose/d; C: no treatment | Y | IT* | 1, 2 |
Liu et al. [42] | 38/38 | T: 58.9 ± 4.8 C: 59.6 ± 4.5 | 55.3 | Depression: CCMD-3, SDS > 50, HAMD-24 > 7 | Lung cancer; stage IIIB to IV | T: Yangfeixiaojijieyu decoction, 1 dose/d; C: no treatment | Y | NIT* | 1, 2, 4 |
Ma et al. [43] | 81/81 | T: 53.9 ± 10.7 C: 56.0 ± 11.9 | 60.5 | Depression: CCMD-2R, HAMD-17 > 18 | Gastric, lung, esophageal, breast, liver and other cancers; any stage | T: Danzhixiaoyao decoction,1 dose/d, 8 weeks; C: no treatment | Y | IT | 1, 2 |
Meng et al. [44] | 78/78 | median T: 61.2 C: 62.2 | 41.0 | Depressive symptoms: SDS > 53 | Esophageal cancer; any stage | T: Chaihushugan decoction alternatively combined with Tongyou decoction; C: no treatment | Y | NIT | 1 |
Meng et al. [45] | 100/100 | T: 68.7 ± 1.4 C: 69.7 ± 1.7 | 31.0 | Depression: CCMD-3, SDS > 50, HAMD-24 > 20 | Breast, gastric, colorectal and lung cancers; any stage | T: Ganmaidazao decoction, 15 d; C: no treatment | Y | IT | 1, 3 |
Sun et al. [46] | 64/64 | T: 46.0 ± 11.7 C: 46.3 ± 12.3 | 100.0 | Depression: ICD-10, DSM, CCMD-3 | Breast cancer; any stage | T: Xiaoyao decoction, 1 dose/d, 6 weeks; C: no treatment | Y | IT | 1, 4, 5 |
Wu et al. [47] | 82/77 | T: 53.4 ± 16.8 C: 52.6 ± 15.7 | 41.5 | Depressive symptoms: HAMD | Gastric cancer; Stage III to IV | T: Shuganjieyu capsule, 0.72 g, bid, 6 weeks; C: no treatment | Y | NIT | 1, 2, 5 |
Fang et al. [48] | 90/90 | T: 42.3 ± 18.1 C: 47.6 ± 16.9 | 54.4 | Depressive symptoms: SDS > 50, HAMD-17 > 14 | Lung, breast, colorectal, liver and other cancers; any stage | T: Chaihushugan decoction, 1 dose/d, 6 weeks; C: fluoxetine, 20 mg qd for 2 weeks, then 20–40 mg qd for 4 weeks | Y | NIT | 1, 2, 5 |
Fu et al. [49] | 26/26 | T: 41–65 C: 39–68 | 42.3 | Depression: CCMD-3, 14 ≤ HAMD-17 ≤ 24 | Breast, esophageal, rectal, nasopharynx, gastric and lung cancers; any stage | T: Suanzaorenjialongmu decoction, 1 dose/d, 6 weeks; C: fluoxetine, 20 mg qd for 2 weeks, then 20–40 mg qd for 4 weeks | NR | NIT | 1, 2, 5 |
Jin et al. [50] | 82/82 | T: 23.8 ± 7.7 C: 22.9 ± 6.9 | NR | Depression: CCMD-3 | Breast cancer; stage I to III | T: Xiaoyao decoction, 1 dose/d, 10 weeks; C: alprazolam,0.4 mg bid, 10 weeks | NR | NIT | 1, 5 |
Liu et al. [27] | 60/60 | T: 51.4 ± 8.7 C: 51.3 ± 6.6 | 100.0 | Depression: CCMD-3, SDS > 50 | Breast cancer; stage I to IIIC | T: Xiaoyao decoction, 1 dose/d, 6 weeks; C: flupenthixol and melitracen, 1 tablet bid, 6 week | NR | IT | 1, 2, 5 |
Ma et al. [51] | 60/60 | 18–80 | 46.7 | Depression: DSM-IV | Breast, esophageal, colorectal, gastric, lung, ovarian, prostatic and liver cancers; stage II to IV | T: Shuganjieyuhuaji decoction, 1 dose/d, 6 weeks; C: fluoxetine 20 mg qd, 6 weeks | NR | NIT | 1, 2, 3 |
Tian et al. [52] | 120/120 | 30–70 | NR | Depression: CCMD-3, HAMD≥16 | Breast, pancreatic, esophageal, lung and gastric cancers; any stage | T: Chaihujialonggumuli decoction,1 dose/d + PT, 6 weeks; C: fluoxetine 20 mg qd + PT, 6 weeks | NR | NIT | 1, 2 |
Zhang et al. [53] | 98/98 | T: 58.0 ± 8.5 C: 57.0 ± 9.4 | 54.1 | Depression: CCMD-3, HAMD> 20 | Breast, colorectal, esophageal, lung and gastric cancers; any stage | T: Ganmaidazao decoction, 1 dose/d, 8 weeks; C: flupenthixol and melitracen 10.5 mg bid, 8 weeks | Y | NIT | 1, 2, 5 |
Zheng et al. [54] | 126/126 | T: 48 ± 16 C: 49 ± 15 | 43.7 | Depression: “diagnosed by psychiatrist” | NR; any stage | T: Chaihushugan decoction, 1 dose/d, 30 days; C: PT | NR | NIT | 2 |
Jia et al. [55] | 78/78 | T: 53.0 ± 3.6 C:53.0 ± 4.2 | 78.2 | Depression: CCMD-2R | Lymphoma, osteosarcoma, breast, liver, endometrial, gastrointestinal, ovarian and renal cancers; any stage | T: oral Chinese herbal medicine decoction, 1 dose/d, 4 weeks; C: fluoxetine 20 mg qd 4 weeks | NR | IT | 2 |
Dai et al. [28] | 80/80 | T: 64.6 ± 10.8 C: 59.7 ± 9.8 | 45.0 | Depression: CCMD, HAMD> 18 | Gastric cancer; any stage | T: Banxiahoupo decoction+liujunzi decoction, 1 dose/d; C: PT | NR | NIT | 2 |
Xu et al. [56] | 58/58 | T: 63.9 ± 10.8 C: 58.9 ± 9.6 | 69.0 | Depression: CCMD, HAMD-17 > 17 | Gastric cancer; any stage | T: Banxiahoupo decoction+liujunzi decoction, 1 dose/d; C: PT | NR | NIT | 1, 2 |